Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Respiratory System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Respiratory System Neoplasm

Cancer Family

Respiratory System Neoplasm

CI-CAN-00000049Explore in graph →

Non-malignant2,727 active trials51 approved drugs619 evidence items

NCIt: C3355
MeSH: D012142

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11611
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (483)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 426–450 of 483 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
· Proc Natl Acad Sci U S A · 2015 · PMID 25733882 · validated civic_curation pubmed
LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
· Acta Pharmacol Sin · 2015 · PMID 26027660 · validated civic_curation pubmed
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
· Cancer Res · 2009 · PMID 19366796 · validated civic_curation pubmed
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
· Cancer Res · 2007 · PMID 18089823 · validated civic_curation pubmed
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
· Cancer Res · 2006 · PMID 16818618 · validated civic_curation pubmed
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.
· Cancer Res · 2017 · PMID 28202511 · validated civic_curation pubmed
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.

Showing 426–450 of 483 publications

← Previous
1
…
17
18
19
20
Next →

· Mol Cancer · 2007 · PMID 17877814 · validated civic_curation pubmed

RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.

· Clin Cancer Res · 2018 · PMID 29127119 · validated civic_curation pubmed

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

· Nat Commun · 2019 · PMID 31399568 · validated civic_curation pubmed

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

· EBioMedicine · 2016 · PMID 26870817 · validated civic_curation pubmed

High-throughput Phenotyping of Lung Cancer Somatic Mutations.

· Cancer Cell · 2016 · PMID 27478040 · validated civic_curation pubmed

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.

· PLoS One · 2007 · PMID 17726540 · validated civic_curation pubmed

Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.

· Anticancer Res · 2015 · PMID 25862853 · validated civic_curation pubmed

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.

· Cell Oncol (Dordr) · 2013 · PMID 23619944 · validated civic_curation pubmed

C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.

· J Thorac Oncol · 2011 · PMID 21964527 · validated civic_curation pubmed

ATP-binding cassette B1 gene polymorphisms, mRNA expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.

· Respirology · 2011 · PMID 21883677 · validated civic_curation pubmed

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

· Oncotarget · 2015 · PMID 26515464 · validated civic_curation pubmed

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

· J Clin Invest · 2006 · PMID 16906227 · validated civic_curation pubmed

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

· Cancer Res · 2008 · PMID 18451166 · validated civic_curation pubmed

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

· Clin Cancer Res · 2008 · PMID 18594010 · validated civic_curation pubmed

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

· Clin Cancer Res · 2012 · PMID 22912387 · validated civic_curation pubmed

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.

· Oncotarget · 2017 · PMID 28947956 · validated civic_curation pubmed

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.

· Oncotarget · 2016 · PMID 26689995 · validated civic_curation pubmed

A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.

· Int J Mol Med · 2009 · PMID 19513541 · validated civic_curation pubmed

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.

· Int J Cancer · 2012 · PMID 21732342 · validated civic_curation pubmed